Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Brandon Fornwalt, the most common co-covered peer. Coverage clusters in ai-models, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Tempus ECG-PH, all published on August 25, 2026.
2 verified stories tracked
Last mentioned: Aug 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Brandon Fornwalt, the most common co-covered peer. Coverage clusters in ai-models, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Tempus ECG-PH, all published on August 25, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tempus ECG-PH. Shared-story counts are live from our verified record — not editorial picks.
Tempus AI announced FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled tool that analyzes standard 12-lead ECGs for pulmonary hypertension signs. The device targets symptomatic adults 40 and older, aiming to address underdiagnosis without invasive procedures.
Tempus's ECG-PH AI model analyzes raw 12-lead ECG waveforms for binary signs associated with elevated mPAP >20 mmHg, receiving FDA 510(k) clearance and marking the company's third cardiovascular AI device. This matters for ML teams as regulatory acceptance of diagnostic AI broadens.
Source: Times Argus · Financialcontent
